Charles W Shrode1, Karen V Draper2, Robert J Huang2, Jamie L W Kennedy3, Adam C Godsey4, Christine C Morrison5, Vanessa M Shami1, Andrew Y Wang1, John A Kern5, James D Bergin3, Gorav Ailawadi5, Dipanjan Banerjee6, Lauren B Gerson7, Bryan G Sauer8. 1. Division of Gastroenterology and Hepatology, University of Virginia, Charlottesville, Virginia. 2. Department of Medicine, Stanford University, Stanford, California. 3. Division of Cardiology, University of Virginia, Charlottesville, Virginia. 4. Department of Medicine, University of Virginia, Charlottesville, Virginia. 5. Division of Cardiothoracic Surgery, University of Virginia, Charlottesville, Virginia. 6. Division of Cardiology, Stanford University, Stanford, California. 7. Division of Gastroenterology and Hepatology, Stanford University, Stanford, California. Electronic address: lgersonmd@yahoo.com. 8. Division of Gastroenterology and Hepatology, University of Virginia, Charlottesville, Virginia. Electronic address: bryansauer@virginia.edu.
Abstract
BACKGROUND & AIMS: The risk of gastrointestinal (GI) bleeding (GIB) and thromboembolic events may increase with continuous-flow left ventricular assist devices (CF-LVADs). We aimed to characterize GIB and thromboembolic events that occurred in patients with CF-LVADs and compare them with patients receiving anticoagulation therapy. METHODS: We performed a retrospective analysis of 159 patients who underwent CF-LVAD placement at 2 large academic medical centers (mean age, 55 ± 13 y). We identified and characterized episodes of GIB and thromboembolic events through chart review; data were collected from a time period of 292 ± 281 days. We compared the rates of GIB and thromboembolic events between patients who underwent CF-LVAD placement and a control group of 159 patients (mean age, 64 ± 15 y) who received a cardiac valve replacement and were discharged with anticoagulation therapy. RESULTS: Bleeding events occurred in 29 patients on CF-LVAD support (18%; 45 events total). Sixteen rebleeding events were identified among 10 patients (range, 1-3 rebleeding episodes/patient). There were 34 thrombotic events among 27 patients (17%). The most common source of bleeding was GI angiodysplastic lesions (n = 20; 44%). GIB and thromboembolic events were more common in patients on CF-LVAD support than controls; these included initial GIB (18% vs 4%, P < .001), rebleeding (6% vs none, P = .001), and thromboembolic events (17% vs 8%, P = .01). CONCLUSIONS: Patients with CF-LVADS receiving anticoagulants have a significantly higher risk of GIB and thromboembolic events than patients receiving anticoagulants after cardiac valve replacement surgery. GI angiodysplastic lesions are the most common source of bleeding.
BACKGROUND & AIMS: The risk of gastrointestinal (GI) bleeding (GIB) and thromboembolic events may increase with continuous-flow left ventricular assist devices (CF-LVADs). We aimed to characterize GIB and thromboembolic events that occurred in patients with CF-LVADs and compare them with patients receiving anticoagulation therapy. METHODS: We performed a retrospective analysis of 159 patients who underwent CF-LVAD placement at 2 large academic medical centers (mean age, 55 ± 13 y). We identified and characterized episodes of GIB and thromboembolic events through chart review; data were collected from a time period of 292 ± 281 days. We compared the rates of GIB and thromboembolic events between patients who underwent CF-LVAD placement and a control group of 159 patients (mean age, 64 ± 15 y) who received a cardiac valve replacement and were discharged with anticoagulation therapy. RESULTS: Bleeding events occurred in 29 patients on CF-LVAD support (18%; 45 events total). Sixteen rebleeding events were identified among 10 patients (range, 1-3 rebleeding episodes/patient). There were 34 thrombotic events among 27 patients (17%). The most common source of bleeding was GI angiodysplastic lesions (n = 20; 44%). GIB and thromboembolic events were more common in patients on CF-LVAD support than controls; these included initial GIB (18% vs 4%, P < .001), rebleeding (6% vs none, P = .001), and thromboembolic events (17% vs 8%, P = .01). CONCLUSIONS:Patients with CF-LVADS receiving anticoagulants have a significantly higher risk of GIB and thromboembolic events than patients receiving anticoagulants after cardiac valve replacement surgery. GI angiodysplastic lesions are the most common source of bleeding.
Authors: Nandan K Mondal; Zengsheng Chen; Jaimin R Trivedi; Erik N Sorensen; Si M Pham; Mark S Slaughter; Bartley P Griffith; Zhongjun J Wu Journal: ASAIO J Date: 2018 Jul/Aug Impact factor: 2.872
Authors: Basem Alkurdi; Klaus Monkemuller; Ali S Khan; Leona Council; Brendan M McGuire; Shajan Peter Journal: Dig Dis Sci Date: 2014-05-13 Impact factor: 3.199
Authors: Haseeb R Jabbar; Ali Abbas; Mustafa Ahmed; Charles T Klodell; Myron Chang; Yunfeng Dai; Peter V Draganov Journal: Dig Dis Sci Date: 2015-06-14 Impact factor: 3.199
Authors: Anthony P Carnicelli; Anjali Thakkar; David J Deicicchi; Andrew C Storm; Jessica Rimsans; Jean M Connors; Mandeep R Mehra; John D Groarke; Michael M Givertz Journal: J Thromb Thrombolysis Date: 2019-04 Impact factor: 2.300